These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36226039)

  • 1. Facilitating bias in cost-effectiveness analysis: CHEERS 2022 and the creation of assumption-driven imaginary value claims in health technology assessment.
    Langley P
    F1000Res; 2022; 11():993. PubMed ID: 36226039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22.
    Langley P
    F1000Res; 2022; 11():248. PubMed ID: 35444797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
    Langley PC
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease.
    Langley PC
    Innov Pharm; 2022; 13(3):. PubMed ID: 36627905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.
    Langley PC
    Innov Pharm; 2018; 9(2):1-5. PubMed ID: 34007702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement, modeling and QALYs.
    Langley PC; McKenna SP
    F1000Res; 2020; 9():1048. PubMed ID: 33093950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic evaluation of preventive digital public health interventions using decision-analytic modelling: a systematized review.
    Lange O
    BMC Health Serv Res; 2023 Mar; 23(1):268. PubMed ID: 36932436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology Assessment.
    Langley PC
    Innov Pharm; 2018; 9(3):1-5. PubMed ID: 34007719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.